(420 days)
No
The 510(k) summary describes a mechanical vacuum-assisted biopsy system and does not mention any AI or ML components or functions.
No
The device is used for diagnostic sampling of breast abnormalities by obtaining tissue samples for histologic examination, not for treating any condition.
Yes
The device, BEXCORE Vacuum Assisted Breast Biopsy System, is indicated to "provide breast tissue samples for diagnostic sampling of breast abnormalities" and for "histologic examination." This process of obtaining tissue for histological evaluation is fundamental to diagnosis.
No
The device description explicitly states it is a "set of equipment used for biopsy composed of a sterilized disposable needle probe unit... and an electronic system unit." This clearly indicates the presence of hardware components beyond just software.
Based on the provided information, the BEXCORE Vacuum Assisted Breast Biopsy System is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples such as blood, urine, or tissue that have been taken from the human body to detect diseases, conditions, or infections. They are used to examine these samples outside of the body.
- BEXCORE System Function: The BEXCORE system is a device used to obtain tissue samples from the breast. It is a biopsy system, which is a procedure performed on the patient's body to collect tissue.
- Purpose of the System: The system's intended use is to provide breast tissue samples for diagnostic sampling. The diagnostic process itself (histologic examination) is performed after the tissue is collected, likely using IVD methods in a laboratory. The BEXCORE system is the tool for obtaining the sample, not for performing the diagnostic test on the sample.
Therefore, the BEXCORE Vacuum Assisted Breast Biopsy System is a medical device used for tissue collection, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The BEXCORE Vacuum Assisted Breast Biopsy System is indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities.
-
It is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
-
It is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality.
The extent of a histologic abnormality cannot always be readily determined from palpation or imaged appearance. Therefore, the extent of removal of the palpated or imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality, e.g., malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures. In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (e.g. fibroadenoma, fibrocystic lesion), the BEXCORE Vacuum Assisted Breast Biopsy System may also be used to partially remove such palpable lesions. Whenever breast tissue is removed. histological evaluation of the standard of care. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
Product codes (comma separated list FDA assigned to the subject device)
KNW, FCG
Device Description
BEXCORE Vacuum-Assisted Breast Biopsy (hereinafter referred to as VABB) system is 'a set of equipment used for biopsy' composed of a sterilized disposable needle probe unit (hereafter Probe) and an electronic system unit. The electronic system unit consists of a driver and a main controller box (hereafter Main Body for main controller box). A biopsy needle-BXC135, BXC140, BXC145 are the Probes approved separately-is mounted on a driver, and then inserted into a breast. The inserted biopsy needle, powered by the motor in the Main Body of BXS100F, could be rotated or moved forward/backward to cut affected tissue of the breast. The cut tissues are pulled out by vacuum pressure to a filter mesh of Probe connected to the vacuum suction unit of BXS100F's Main Body. At the moment of completing tissue cut, the air supplied from a Main Body to the front part of the biopsy needle makes easy to discharge the cut tissue smoothly.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
ultrasound
Anatomical Site
Breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical bench tests were performed on the BEXCORE Biopsy Needle System and compared to the predicate device.
- Ability to extract a biopsy tissue sample
- Average Tissue Length
- Edge of Cut Sample Evaluation
- Average Tissue Weight
- Multiple Sample Operation of the BEXCORE Biopsy Needle
- Vacuum Pressure
- Safety Feature (Cover) of the BEXCORE Biopsy Needle
- Force to Arm the BEXCORE Biopsy Needle
- Force to Advance the BEXCORE Biopsy Needle
- BEXCORE Biopsy Needle Obstruction Test
- Tissue sample dimensions, firmness for combinations of jaw size, vacuum settings
All of these performance tests demonstrate the device performs according to its intended use and meets the performance specifications.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 876.1075 Gastroenterology-urology biopsy instrument.
(a)
Identification. A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification. (1) Class II (performance standards).(2) Class I for the biopsy forceps cover and the non-electric biopsy forceps. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
Image /page/0/Picture/0 description: The image contains the logos of the Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
August 20, 2018
Medical Park CO., LTD % Mr. Dave Kim, MBA Medical Device Regulatory Affairs 8310 Buffalo Speedway Houston, Texas 77025
Re: K171890
Trade/Device Name: BEXCORE Breast Biopsy System, Biopsy Needle BXC135, BXC140, BXC145 Biopsy Needle Regulation Number: 21 CFR 876.1075 Regulation Name: Gastroenterology-Urology Biopsy Instrument Regulatory Class: Class II Product Code: KNW, FCG Dated: July 16, 2018 Received: July 23, 2018
Dear Mr. Kim:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/ofdocs/ofpmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice. labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entiled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Jennifer R. Stevenson -
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K171890
Device Name
BEXCORE Vacuum Assisted Breast Biopsy System; BXC135, BXC140, BXC145 Biopsy Needle
Indications for Use (Describe)
The BEXCORE Vacuum Assisted Breast Biopsy System is indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities.
-
It is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
-
It is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality.
The extent of a histologic abnormality cannot always be readily determined from palpation or imaged appearance. Therefore, the extent of removal of the palpated or imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality, e.g., malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures. In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (e.g. fibroadenoma, fibrocystic lesion), the BEXCORE Vacuum Assisted Breast Biopsy System may also be used to partially remove such palpable lesions. Whenever breast tissue is removed, histological evaluation of the tissue is the standard of care. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
| CONTINUE ON A SEPARATE PAGE IF NEEDED. |
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW *
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
K171890
510(k) Summary
Date 510k summary prepared: August 16, 2018
I. SUBMITTER
| Submitter's Name | Medical Park Co., Ltd. | ||
|---|---|---|---|
| Submitter's Address | #601/623/624/901, Knowledge-Industry | ||
| Center, | |||
| BundangSuji U-Tower, 767, Sinsu-ro, Suji-gu | |||
| Yongin-si, Gyeonggi-do, Korea | |||
| Submitter's Telephone | +82 (070) 4800-6532 | ||
| Contact person | Ms. Hye-Yeon Park, / RA Manager | ||
| hypark @ medicalpark.co.kr | |||
| Official Correspondent | Mtech Group | ||
| Dave Kim, MBA, President | |||
| davekim@mtech-inc.net | |||
| Address | 8310 Buffalo Speedway, Houston, TX 77025 | ||
| Telephone | +713-467-2607 |
DEVICE II.
| Trade/proprietary Name | BEXCORE Vacuum Assisted Breast Biopsy System
BXC135, BXC140, BXC145 Biopsy Needles |
|------------------------|---------------------------------------------------------------------------------------|
| Common or Usual Name | Vacuum Assisted Breast Biopsy System & Needle |
| Regulation Name | Gastroenterology-urology biopsy instrument |
| Regulation Number | 21 CFR 876.1075 (Product Code: KNW, FCG) |
| Regulatory Class | Class II |
III. PREDICATE DEVICE
| Primary Manufacturer | SenoRx, Inc |
|---|---|
| Device Name | EnCor Breast Biopsy System |
| 510(k) Number | K093512(Decision Date - Nov 20, 2009) |
| Regulation Name | Gastroenterology-urology biopsy instrument |
| Regulation Number | 21 CFR 876.1075 (Product Code: KNW) |
| Regulatory Class | Class II |
4
IV. REFERENCE DEVICE
| Primary Manufacturer | PFM Medical, Inc |
|---|---|
| Device Name | Safety Biopsy Needle System |
| Safety Biopsy Needle and Safety Coaxial Needle | |
| 510(k) Number | K140137(Decision Date – March 25, 2014) |
| Regulation Name | Gastroenterology-urology biopsy instrument |
| Regulation Number | 21 CFR 876.1075 (Product Code: FCG) |
| Regulatory Class | Class II |
V. DEVICE DESCRIPTION
BEXCORE Vacuum-Assisted Breast Biopsy (hereinafter referred to as VABB) system is 'a set of equipment used for biopsy' composed of a sterilized disposable needle probe unit (hereafter Probe) and an electronic system unit. The electronic system unit consists of a driver and a main controller box (hereafter Main Body for main controller box). A biopsy needle-BXC135, BXC140, BXC145 are the Probes approved separately-is mounted on a driver, and then inserted into a breast. The inserted biopsy needle, powered by the motor in the Main Body of BXS100F, could be rotated or moved forward/backward to cut affected tissue of the breast. The cut tissues are pulled out by vacuum pressure to a filter mesh of Probe connected to the vacuum suction unit of BXS100F's Main Body. At the moment of completing tissue cut, the air supplied from a Main Body to the front part of the biopsy needle makes easy to discharge the cut tissue smoothly.
VI. INDICATIONS FOR USE:
The BEXCORE Vacuum-Assisted Breast Biopsy System is indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities.
-
It is intended to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
-
It is intended to provide breast tissue for histologic examination with partial removal of a palpable abnormality.
The extent of a histologic abnormality cannot always be readily determined from palpation or imaged appearance. Therefore, the extent of removal of the palpated or imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality, e.g., malignancy. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures. In instances when a patient presents with a palpable abnormality that has been classified as benign through clinical and/or radiological criteria (e.g. fibroadenoma, fibrocystic lesion), the BEXCORE Vacuum-Assisted Breast Biops v System may also be used to partially remove such palpable lesions. Whenever breast tissue is removed. histological evaluation of the standard of care. When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
5
Substantial Equivalence VII.
BEXCORE Vacuum Assisted Breast Biopsy System is substantially equivalent to EnCor (K093512). The following comparison table is presented to demonstrate substantial equivalence.
| SUBJECT DEVICE | Predicate 1 | Remarks | |
|---|---|---|---|
| 510(k) Number | K171890 | K093512 | - |
| Device | |||
| Trade(Brand) Name | BEXCORE Vacuum-Assisted | ||
| Breast Biopsy System | |||
| BXC135, BXC140, BXC145 Biopsy | |||
| Needles | EnCor Breast Biopsy System | - | |
| Common Name | Biopsy System | Biopsy System | - |
| Manufacturer | MEDICAL PARK CO., Ltd.. | SenoRx, Inc. | - |
| Intended Use | The BEXCORE Vacuum-Assisted | ||
| Breast Biopsy System is indicated | |||
| to provide breast tissue samples | |||
| for diagnostic sampling of breast | |||
| abnormalities. |
- It is intended to provide breast
tissue for histologic examination
with partial or complete removal
of the imaged abnormality. - It is intended to provide breast
tissue for histologic examination
with partial removal of a
palpable abnormality.
The extent of a histologic
abnormality cannot always be
readily determined from
palpation or imaged appearance.
Therefore, the extent of removal
of the palpated or imaged
evidence of an abnormality does
not predict the extent of removal
of a histologic abnormality, e.g.,
malignancy. When the sampled
abnormality is not histologically
benign, it is essential that the
tissue margins be examined for
completeness of removal using
standard surgical procedures. In
instances when a patient
presents with a palpable
abnormality that has been
classified as benign through
clinical and/or radiological
criteria (e.g. fibroadenoma,
fibrocystic lesion), the BEXCORE | The EnCor Breast Biopsy System
is indicated to provide breast
tissue samples for diagnostic
sampling of breast
abnormalities. - It is intended to provide breast
tissue for histologic examination
with partial or complete removal
of the imaged abnormality. - It is intended to provide breast
tissue for histologic examination
with partial removal of a
palpable abnormality.
The extent of a histologic
abnormality cannot always be
readily determined from
palpation or imaged appearance.
Therefore, the extent of removal
of the palpated or imaged
evidence of an abnormality does
not predict the extent of removal
of a histologic abnormality, e.g.,
malignancy. When the sampled
abnormality is not histologically
benign, it is essential that the
tissue margins be examined for
completeness of removal using
standard surgical procedures. In
instances when a patient
presents with a palpable
abnormality that has been
classified as benign through
clinical and/or radiological
criteria (e.g. fibroadenoma,
fibrocystic lesion), the EnCor | Same |
| | | | |
| | be used to partially remove such
palpable lesions. Whenever
breast tissue is removed,
histological evaluation of the
tissue is the standard of care.
When the sampled abnormality
is not histologically benign, it is
essential that the tissue margins
be examined for completeness
of removal using standard
surgical procedures | be used to partially remove such
palpable lesions. Whenever
breast tissue is removed,
histological evaluation of the
tissue is the standard of care.
When the sampled abnormality
is not histologically benign, it is
essential that the tissue margins
be examined for completeness
of removal using standard
surgical procedures | |
| needle,
cannula(s), | 8G, 10G and 12G | 7G, 10G and 12G | Same |
| jaw size | 5mm, 10mm, 15mm, 20mm | 10mm, 20mm | Different |
| mode of action | Vacuum-assisted device to
remove breast tissue, single
puncture and multiple samples,
brush rotation, suction scraping,
for use with ultrasound | Vacuum-assisted device to
remove breast tissue, single
puncture and multiple samples,
brush rotation, suction, scraping,
for use with ultrasound | Same |
| electrica | 100120VAC 6A, 50/60Hz,, 10A, 50/60Hz
460VA | 110-120V
220-240V~, 10A, 50/60Hz | Similar |
| Material come
into patient
contact : Needle | Needle: stainless steel | Needle: stainless steel | Same |
| vacuum pressure | -LOW: -15kPa ~ -35kPa
-MID: -35kPa ~ -55kPa
-HIGH: -55kPa ~ -80kPa | -82.4kPa | Different |
| method of
placement; and
other related
information | A biopsy of breast tissue must
be taken only at the position
diagnosed and determined
based on the ultrasound image.
Device operate with foot
switches and driver(holster). | A biopsy of breast tissue must
be taken only at the position
diagnosed and determined
based on the ultrasound image.
Device operate with foot
switches and driver(holster). | Same |
| Single Use
Component | Vacuum- Assisted Breast Biopsy
Needle | Vacuum- Assisted Breast Biopsy
Needle | Same |
| Reusable
Component | Suction canister, Hand driver,
Foot switch | Suction canister, Hand driver,
Foot switch | Same |
| Electrical | 120V, 60Hz, 5A, 460VA | Free voltage | Same |
6
VIII. DESCRIPTION THE DIFFERENCES OF SUBJECT DEVICE AND PREDICATE DEVICE
BEXCORE Vacuum Assisted Breast Biopsy System has the same indications for use. It shows equivalent specifications with the predicate devices in most of parameters. The main difference is that the subject device offers different Jaw size and has a lower vacuum pressure range than the predicate devices.
Despite the differences above, the performance test results submitted in this 510k shows that the subject device is substantially equivalent to the predicate devices in safety and effectiveness.
7
Performance Testing IX.
Performance testing of the Bexcore Vacuum Assisted Biopsy Needle System was conducted in accordance with the following international standards:
"Guidance on Premarket Notification [51 0(k)] for Medical Devices with Sharps Injury Prevention Features; Guidance for Industry and FDA. 03/01/1995
"Guidance for the Content of Premarket Notifications for Biopsy Devices Used in Gastroenterology and Urology"
"AAMI/ANSI/ISO 10993-1:2009, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing, and the FDA Modified Safety & ISO 10993 Test Profile
-
AAMI/ANSI/ISO 1 0993-7:-2008, Biological Evaluation of Medical Devices Part 7: Ethylene Oxide Sterilization Results
-
AAMI/ANSI/ISO 11135:2007, Sterilization of Healthcare Products Ethylene oxide - Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices
-
ISO 14971:2007, Medical Devices - Risk Management for Medical Devices.
Pyrogen Test and Endotoxin Test were conducted based on "ISO 10993-11: 2006, Information on material mediated pyrogens which is FDA recognized standard (recognition no: 2-176).
The EMC and Electrical safety tests are conducted based on the currently FDA-recognized version of standards.
IEC 60601-1-2: 2007 is FDA recognized IEC standard (Recognition No: 19-1).
IEC 60601-1 Electrical Safety Test report contains the US National Differences – Differences according to US National standard ANSI/AAMI ES6060-1-: 2005 / A2: 2010.
Furthermore, the following non-dinical bench tests were performed on the BEXCORE Biopsy Needle System and compared to the predicate device.
-
- Ability to extract a biopsy tissue sample
-
- Average Tissue Length
-
- Edge of Cut Sample Evaluation
-
- Average Tissue Weight
-
- Multiple Sample Operation of the BEXCORE Biopsy Needle
-
- Vacuum Pressure
-
- Safety Feature (Cover) of the BEXCORE Biopsy Needle
-
- Force to Arm the BEXCORE Biopsy Needle
-
- Force to Advance the BEXCORE Biopsy Needle
-
- BEXCORE Biopsy Needle Obstruction Test
8
- Tissue sample dimensions, firmness for combinations of jaw size, vacuum settings
All of these performance tests demonstrate the device performs according to its intended use and meets the performance specifications.
Summary X.
Based on the indications for use and safety and performance testing, the BEXCORE Vacuum Assisted Biopsy Needle System meets the requirements that are considered for its intended use and is substantially equivalent in design materials, sterilization, and indications for use. The conclusions drawn from the nonclinical tests demonstrate that the device is as safe and effective as the legally marketed device.